ImageneBio (IMA) Revenue (2020 - 2025)

ImageneBio (IMA) posted Revenue of $800000.0 for Q1 2025, down 77.14% sequentially from $3.5 million in Q3 2024.

ImageneBio (IMA) Revenue (2020 - 2025) Analysis & Trends

ImageneBio has reported Revenue for 6 years, with the latest figure at $800000.0 in Q1 2025.

Quarterly Revenue changed N/A year-over-year to $800000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $6.1 million (changed N/A YoY) and the FY2023 annual result came in at $9.2 million, down 41.35% from the prior year.
Revenue fell to $800000.0 in Q1 2025 per IMA's latest filing, from $3.5 million in the prior quarter.
Over five years, Revenue peaked at $20.2 million in Q4 2021 and troughed at $382000.0 in Q2 2022.
A 5-year average of $4.3 million and a median of $3.5 million in 2021 frame the typical range for Revenue.
The sharpest annual moves came in 2021 and 2022: Revenue jumped 31003.08% in 2021, then tumbled 89.24% in 2022.
Over 5 years, Revenue stood at $20.2 million in 2021, then slumped by 73.04% to $5.4 million in 2022, then slumped by 87.91% to $659000.0 in 2023, then jumped by 431.11% to $3.5 million in 2024, then sank by 77.14% to $800000.0 in 2025.
According to Business Quant data, Revenue over the past three periods registered $800000.0, $3.5 million, and $659000.0 for Q1 2025, Q3 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	ImageneBio	48.60 Mn	-86.75 Mn	-	-

Download Data